Merck Shares Up 1.14% to $117.11 Ahead of April 30 EPS, $16B Revenue Forecast
Merck shares rose 1.14% to $117.11, outperforming the S&P 500’s 0.83% gain and the Nasdaq’s 1.38% advance. Investors focus on April 30 earnings where consensus projects EPS of -$0.57 (down 125.68%) and revenue of $16.01 billion (up 3.09%).
1. Share Price Performance
Merck shares climbed 1.14% to $117.11 in the latest session, outpacing the S&P 500’s gain of 0.83%, the Dow’s 0.5%, and the Nasdaq’s 1.38%. The advance follows a prior decline of 5.04% that lagged the medical sector’s 3.46% drop and the S&P 500’s 2.65% retreat.
2. Upcoming Q1 Earnings Estimates
Merck is set to release first-quarter results on April 30, with a consensus EPS forecast of -$0.57 representing a 125.68% year-over-year decrease, alongside projected revenue of $16.01 billion, up 3.09% from the prior year.
3. Valuation Metrics and Zacks Rank
The stock trades at a forward P/E of 21.18 versus the industry average of 15.83 and carries a PEG ratio of 2.11 compared to the industry’s 2.24. Merck holds a Zacks Rank #4 (Sell) and its industry position in the bottom 19% reflects a modest short-term outlook.